Therapeutic delays lead to worse survival among patients with Hepatocellular carcinoma

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 9, 2013, Pages 1101-1108

  Singal, Amit G ^a,b   Waljee, Akbar K ^c   Patel, Nishant ^a   Chen, Emerson Y ^a   Tiro, Jasmin A ^a,b   Marrero, Jorge A ^a   Yopp, Adam C ^b,d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ASCITES; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; THERAPY DELAY; URBAN AREA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CLINICAL COMPETENCE; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84885103182     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0131     Document Type: Article

References (27)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576. (Pubitemid 46890874)
2. Singal AG, Marrero JA. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol 2010;26:189-195.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2010;53:1-35.
4. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-1491.
5. Singal A, Volk ML, Waljee A, et al. Meta-Analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009;30:37-47.
6. Davila JA, Morgan RO, Richardson PA, et al. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 2010;52:132-141.
7. Singal AG, Conjeevaram HS, Volk ML, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev 2012;21:793-799.
8. Singal AG, Nehra M, Huet B, et al. Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastro 2013;108:425-432.
9. Singal AG, Yopp A, Skinner CS, et al. Utilization of hepatocellular carcinoma surveillance among american patients: a systematic review. J Gen Intern Med 2012;27:861-867.
10. Singal AG, Yopp AC, Gupta S, et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila) 2012;5:1124-1130.
11. Fahmy NM, Mahmud S, Aprikian AG. Delay in the surgical treatment of bladder cancer and survival: systematic review of the literature. Eur Urol 2006;50:1176-1182. (Pubitemid 44692926)
12. Korsgaard M, Pedersen L, Sorensen HT, Laurberg S. Delay of treatment is associated with advanced stage of rectal cancer but not of colon cancer. Cancer Detect Prev 2006;30:341-346. (Pubitemid 44402897)
13. Langenbach MR, Schmidt J, Neumann J, Zirngibl H. Delay in treatment of colorectal cancer: multifactorial problem. World J Surg 2003;27:304-308. (Pubitemid 36920142)
14. McLaughlin JM, Anderson RT, Ferketich AK, et al. Effect on survival of longer intervals between confirmed diagnosis and treatment initiation among low-income women with breast cancer. J Clin Oncol 2012;30:4493-4500.
15. Richards MA, Westcombe AM, Love SB, et al. Influence of delay on survival in patients with breast cancer: a systematic review. Lancet 1999;353:1119-1126. (Pubitemid 29155203)
16. Ashing-Giwa KT, Gonzalez P, Lim JW, et al. Diagnostic and therapeutic delays among a multiethnic sample of breast and cervical cancer survivors. Cancer 2010;116:3195-3204.
17. Kubota K, Ina H, Okada Y, Irie T. Growth rate of primary single hepatocellular carcinoma: determining optimal screening interval with contrast enhanced computed tomography. Dig Dis Sci 2003;48:581-586. (Pubitemid 36324168)
18. Tan D, Yopp A, Beg MS, et al. Meta-Analysis: underutilisation and disparities of treatment among patients wtih hepatocellular carcinoma in the United States. Aliment Pharmacol Ther, in press.
19. Shah SA, Smith JK, Li Y, et al. Underutilization of therapy for hepatocellular carcinoma in the medicare population. Cancer 2011;117:1019-1026.
20. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236. (Pubitemid 43112690)
21. Cillo U, Vitale A, Grigoletto F, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 2006;44:723-731.
22. Singal AG, Tiro JA, Gupta S. Improving hepatocellular carcinoma screening: applying lessons from colorectal cancer screening. Clin Gastroenterol Hepatol 2013;11:472-477.
23. Davila JA, Kramer JR, Duan Z, et al. Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Hepatology 2013;57:1858-1868.
24. Artinyan A, Mailey B, Sanchez-Luege N, et al. Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States. Cancer 2010;116:1367-1377.
25. Sloane D, Chen H, Howell C. Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival. J Natl Med Assoc 2006;98:1934-1939. (Pubitemid 44955937)
26. Davila JA, El-Serag HB. Racial differences in survival of hepatocellular carcinoma in the United States: a population-based study. Clin Gastroenterol Hepatol 2006;4:104-110; quiz 4-5. (Pubitemid 43129531)
27. Siegel AB, McBride RB, El-Serag HB, et al. Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002. Am J Gastroenterol 2008;103:120-127.